source
- EU regulators back Minoryx’s ALD therapy while rejecting Zevra’s rare-disease drugThe EU Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on Minoryx Therapeutics' drug for adrenoleukodystrophy, marking a significant regulatory step after previous c…
- U.S. drug shortages stem from weak regulation, not China competition, says expertIn 2025 the United States faced 216 active drug shortages, limiting access to lifesaving medicines for patients. While the White House and national‑security officials have framed the problem as a…